CYPH CYPHERPUNK TECHNOLOGIES INC.
$2.21 +31.55%
Updated
Healthcare · Pharmaceutical Preparations
CYPHERPUNK TECHNOLOGIES INC. (CYPH) is a healthcare company in the Pharmaceutical Preparations industry, with a market capitalization of $238 million. Shares last traded at $2.21, 42.1% below their 52-week high. Net profit margin is -58.5%, below the peer median of -8.9%. Revenue grew 0.0% year over year.
Market Cap
$238M
Shares Out
107.8M
EPS (TTM)
$-2.30
P/E Ratio
—
P/S Ratio
158.77
P/B Ratio
1.71
Dividend / Share
—
Dividend Yield
—
52-Week High
$3.82
52-Week Low
$0.49
Volume
541,511
Avg Vol (3m)
132,639.889
Performance
1W
+16.32%
1M
+200.52%
3M
+125.93%
6M
+258.42%
YTD
+95.58%
1Y
—
Chart
Full chart →Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.
Technicals
RSI (14)
78.04
SMA (50)
$0.91
SMA (200)
$0.98
Price vs SMA50
+141.82%
Price vs SMA200
+126.13%
ATR (14)
$0.22
Financials
Revenue
$2M
Net Income
$-1M
Gross Margin
—
Operating Margin
—
Net Margin
-58.5%
Return on Equity
-0.6%
Return on Assets
-0.6%
Current Ratio
79.19
Debt / Equity
0.03
Revenue Growth (YoY)
+0.0%
Latest reported annual period ending 2026-06-30 · SEC EDGAR/XBRL.
Recent earnings
| Period | EPS (diluted) | Reported |
|---|---|---|
| Q2 2026 | $-0.21 | 2026-08-12 |
| Q1 2026 | $-0.46 | 2026-05-14 |
| FY 2025 | $0.07 | 2026-03-16 |
| Q3 2025 | $-0.85 | 2025-11-12 |
| Q2 2026 | $-0.78 | 2026-08-12 |
| Q1 2026 | $-0.37 | 2026-05-14 |
Pharmaceutical Preparations peers
CYPH vs 14 industry peers (Pharmaceutical Preparations), by market cap. Updated
P/S vs peers
158.77 / 11.11 med
+1329% premium
Net margin vs peers
-58.5% / -8.9% med
below median
1–14 of 14
| LLY | Lilly (Eli) | $1.09T | 40.86 | 13.70 | 33.5% | -0.02% |
| JNJ | Johnson & Johnson | $670.6B | 31.88 | 6.85 | 21.5% | +1.04% |
| ONC | Beone Medicines Ltd. | $535.9B | 817.25 | 87.43 | 10.7% | +0.23% |
| ABBV | AbbVie | $459.8B | 72.87 | 7.14 | 9.8% | -0.57% |
| MRK | Merck | $375.8B | 118.44 | 5.65 | 4.8% | +0.44% |
| ABT | Abbott Laboratories | $189.5B | 30.20 | 4.20 | 13.9% | -1.50% |
| PFE | Pfizer | $164.2B | 37.91 | 2.58 | 6.8% | -0.76% |
| VRTX | Vertex Pharmaceuticals | $141.5B | 32.11 | 11.24 | 35.0% | +0.24% |
| BMY | Bristol Myers Squibb | $139.1B | 14.98 | 2.83 | 18.9% | +0.62% |
| REGN | Regeneron Pharmaceuticals | $87.2B | 20.15 | 5.61 | 27.9% | -1.02% |
| TEVA | Teva Pharmaceutical Industries Ltd | $42.6B | 60.41 | 2.46 | 4.1% | -2.32% |
| ALNY | Alnylam Pharmaceuticals | $35.4B | 43.77 | 9.52 | 21.8% | -1.10% |
| ZTS | Zoetis | $31.5B | 12.05 | 3.31 | 27.5% | +0.16% |
| RPRX | Royalty Pharma Plc | $28.2B | 34.56 | 11.11 | 32.1% | +1.24% |
Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.